Clinical trials: Chronic HCV Infection
Chronic Hepatitis C
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C
The efficacy of combination antiviral therapy for chronic hepatitis C is influenced by many factors. Important patient-specific factors include, age, gender, race, body weight.
- Trial name
- NCT01464008
- Testing
- Pegylated interferon alfa-2a and ribavirin
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children
Chronic hepatitis C virus (HCV) infection represents a crucial health problem in children that greatly influence their quality of life.
- Trial name
- NCT05091008
- Testing
- Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Mansoura University Children Hospital
Hepatitis C, Chronic
Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV
Current treatments for Hepatitis C virus (HCV) have severe side effects and are very expensive. There is a need to explore effective natural therapies against HCV that are less toxic and more cost-effective.
- Trial name
- NCT02690103
- Testing
- pegylated IFN, Biobran, Ribavirin
- Volunteers
- 37 people
- Sponsor
- Cairo University
Hepatitis C, Chronic
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)
This is a study to determine the pharmacokinetics (PK) and weight-based dose of boceprevir following single oral dose administration in Chronic Hepatitis C Virus (HCV) pediatric participants.
- Trial name
- NCT01425190
- Testing
- Boceprevir
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hepatitis C
Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)
Adherence to the prescribed treatment regimen with PegIntron and Rebetol affects the chance of achieving a sustained virologic response in patients with hepatitis C.
- Trial name
- NCT00705107
- Testing
- PegIntron pen (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 267 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Liver Disease
Genetics of Hepatitis C Virus Infection
The diverse clinical syndromes associated with hepatitis C underscore the multifactorial and polygenic nature of HCV infection. Both viral and host factors likely contribute to variations in infection outcome, disease…
- Trial name
- NCT00005657
- Where
- United States
- Volunteers
- 870 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Viral Hepatitis C, Monoclonal B-Cell Lymphocytosis
Study to Assess Monoclonal B-Cell Lymphocytosis in Individuals With Chronic Hepatitis C
This study evaluates the incidence of monoclonal B-cell lymphocytosis MBL) in patients with chronic hepatitis C and to determine if monoclonal b-cell lymphocytosis is affected by treatment for hepatitis C.
- Trial name
- NCT06564051
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Hepatitis C Virus (HCV)
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
The objectives of this study are to assess the pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir adult formulation in adolescents ages 12 to 17 years and a pediatric formulation of glecaprevir and pibrentasvir in…
- Trial name
- DORA (NCT03067129)
- Testing
- Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
- Where
- 38 sites in United States, Belgium and 7 more
- Volunteers
- 129 people
- Sponsor
- AbbVie
Chronic HCV Infection
Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus
This is an interventional Phase II/III, single center, single arm clinical trial to assess the pharmacokinetics, efficacy, safety and tolerance of daclatasvir plus sofosbuvir in treatment-naïve, non-cirrhotic adolescents with…
- Trial name
- NCT03540212
- Testing
- Daclatasvir and sofosbuvir
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Hepatitis C
Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients
The results of antiviral therapy in patients with recurrent hepatitis C after liver transplantation are lower than standard. Ribavirin has immune-modulating effects and seems to be crucial to optimize viral treatment.
- Trial name
- RBV (NCT00993122)
- Testing
- ribavirin pre-treatment
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Chronic Pain, Chronic Pain Syndrome
Outcomes Mandate National Integration With Cannabis as Medicine
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
- Conditions
- Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma
- Trial name
- OMNI-Can (NCT03944447)
- Testing
- Cannabis, Medical, RYAH-Medtech Inhaler
- Where
- 17 sites in United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- OMNI Medical Services, LLC
Hepatitis C
Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
The interferon- and ribavirin- (RBV) free combination regimen of glecaprevir plus pibrentasvir (GLE/PIB) for the treatment of genotypes 1 to 6 of chronic hepatitis C (CHC) viral infection has been shown to be safe and effective…
- Trial name
- NCT03303599
- Where
- 156 sites in Austria, Belgium and 7 more
- Volunteers
- 2,118 people
- Sponsor
- AbbVie
Hepatitis C
Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
An observational, postmarketing commitment following the marketing authorization for DCV Trio therapy in Japan
- Trial name
- NCT03071133
- Where
- Japan
- Volunteers
- 344 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
This study will have two parts as follows: The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric…
- Trial name
- NCT02175758
- Testing
- SOF, RBV
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
HCC in Chronic HCV Patients With Advanced Liver Fibrosis
Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals
Chronic HCV infection has relatively slow rate of progression. Liver fibrosis is the main sequlae and usually progressed to cirrhosis after long period (10 to 20 years) [6].
- Trial name
- NCT03884062
- Testing
- DAAs
- Volunteers
- 3,000 people
- Sponsor
- Egyptian Liver Hospital
Hepatitis C, Chronic
Re-engaging Patients With Hepatitis C Into Care
Aims: To evaluate the impact of a letter, phone call and incentive in re-engaging patients with hepatitis C care. Outcomes of interest: Primary outcome of interest: Attendance for assessment of liver disease within 4 months of…
- Trial name
- NCT04029246
- Testing
- Follow up phone call, Incentive
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Glasgow Royal Infirmary
Hepatitis C
History of Hepatitis C in Volunteer Blood Donors
Hepatitis C is a disease of the liver caused by the Hepatitis C Virus (HCV). Patients with hepatitis C may feel well and show no signs or symptoms of being ill.
- Trial name
- NCT00001982
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C
Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin
Genotype 1 CHC participants from Study SPC3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy…
- Trial name
- NCT02508090
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection
Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection
The primary objective of this study is to evaluate the steady-state pharmacokinetics (PK) and confirm the age-appropriate dose of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) in pediatric…
- Trial name
- NCT03820258
- Testing
- SOF/VEL/VOX
- Where
- 10 sites in Italy, Poland and 1 more
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) infection in pediatric participants who are undergoing cancer…
- Trial name
- NCT02868242
- Testing
- LDV/SOF
- Where
- Egypt
- Volunteers
- 19 people
- Sponsor
- Gilead Sciences